Erste Group Bank Issues Optimistic Forecast for NVO Earnings

Novo Nordisk A/S (NYSE:NVO) – Erste Group Bank increased their FY2026 earnings per share estimates for Novo Nordisk A/S in a research note issued on Friday, June 5th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.27 per share for the year, up from their prior estimate of $3.23. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.45 per share.

Other research analysts also recently issued research reports about the company. TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research note on Tuesday, March 10th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research note on Tuesday, March 3rd. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price on the stock. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Finally, Wolfe Research assumed coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $43.98 on Friday. The business’s 50-day moving average price is $42.13 and its two-hundred day moving average price is $46.01. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The company has a market capitalization of $196.37 billion, a P/E ratio of 10.32, a price-to-earnings-growth ratio of 3.83 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion for the quarter.

Institutional Trading of Novo Nordisk A/S

Several large investors have recently made changes to their positions in NVO. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $25,000. WealthCollab LLC lifted its position in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $28,000. Jackson Grant Investment Advisers Inc. acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Maseco LLP acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Novo Nordisk’s Wegovy pill, the company’s first daily oral weight-management treatment, expanding its obesity lineup beyond injectable products and potentially opening a new growth channel. Reuters article
• Positive Sentiment: Analysts at Erste Group Bank raised their FY2026 EPS estimate for Novo Nordisk, suggesting expectations remain supportive for earnings despite recent volatility. MarketBeat report
• Positive Sentiment: Separate coverage highlighted Novo Nordisk as a large-cap value idea and pointed to recent Phase 3 obesity-trial data, reinforcing investor enthusiasm for its GLP-1 pipeline and long-term market position. Yahoo Finance article
• Neutral Sentiment: Novo Nordisk’s stock has been trading around the mid-$40s, with recent commentary noting it outperformed the broader market in the latest session, but the move appears tied to news flow rather than a single earnings catalyst. Yahoo Finance article
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to limited internal systems and possible data copying, which could pressure sentiment if the breach becomes more serious or raises governance concerns. Reuters article
• Negative Sentiment: Some U.S. employers are considering dropping GLP-1 obesity-drug coverage in 2027, a potential demand risk for Novo Nordisk’s Wegovy franchise if broader reimbursement weakens. Reuters article

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.